5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Sociodemographic and behavioural factors associated with testing for HIV and STIs in a US nationwide sample of transgender men who have sex with men

      , , ,
      Sexually Transmitted Infections
      BMJ

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          Transgender men who have sex with men (TMSM) represent an understudied population in relation to screening for HIV and sexually transmitted infections (STIs). We examined HIV and STI testing prevalence among TMSM along with the factors associated with testing in a diverse US nationwide sample of TMSM.

          Methods

          Data from a cross-sectional online convenience sample of 192 TMSM were analysed using multivariable binary logistic regression models to examine the association between sociodemographic and behavioural factors and lifetime testing for HIV, bacterial STIs and viral STIs, as well as past year testing for HIV.

          Results

          More than two-thirds of TMSM reported lifetime testing for HIV (71.4%), bacterial STIs (66.7%), and viral STIs (70.8%), and 60.9% had received HIV testing in the past year. Engaging in condomless anal sex with a casual partner whose HIV status is different or unknown and having fewer than two casual partners in the past 6 months were related to lower odds of lifetime HIV, bacterial STI, viral STI and past year HIV testing. Being younger in age was related to lower probability of testing for HIV, bacterial STIs and viral STIs. Furthermore, TMSM residing in the South were less likely to be tested for HIV and viral STIs in their lifetime, and for HIV in the past year. Finally, lower odds of lifetime testing for viral STIs was found among TMSM who reported no drug use in the past 6 months.

          Conclusions

          These findings indicate that a notable percentage of TMSM had never tested for HIV and bacterial and viral STIs, though at rates only somewhat lower than among cisgender MSM despite similar patterns of risk behaviour. Efforts to increase HIV/STI testing among TMSM, especially among those who engage in condomless anal sex, are needed.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Barriers and facilitators to HIV and sexually transmitted infections testing for gay, bisexual, and other transgender men who have sex with men.

          Transgender men who have sex with men (trans MSM) may be at elevated risk for HIV and other sexually transmitted infections (STI), and therefore require access to HIV and STI testing services. However, trans people often face stigma, discrimination, and gaps in provider competence when attempting to access health care and may therefore postpone, avoid, or be refused care. In this context, quantitative data have indicated low access to, and uptake of, HIV testing among trans MSM. The present manuscript aimed to identify trans MSM's perspectives on barriers and facilitators to HIV and STI testing. As part of a community-based research project investigating HIV risk and resilience among trans MSM, 40 trans MSM aged 18 and above and living in Ontario, Canada participated in one-on-one qualitative interviews in 2013. Participants described a number of barriers to HIV and other STI testing. These included both trans-specific and general difficulties in accessing sexual health services, lack of trans health knowledge among testing providers, limited clinical capacity to meet STI testing needs, and a perceived gap between trans-inclusive policies and their implementation in practice. Two major facilitators were identified: access to trusted and flexible testing providers, and integration of testing with ongoing monitoring for hormone therapy. Based on these findings, we provide recommendations for enhancing access to HIV and STI testing for this key population.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A global research synthesis of HIV and STI biobehavioural risks in female-to-male transgender adults.

            There is a growing interest in HIV infection and sexually transmitted infection (STI) disease burden and risk among transgender people globally; however, the majority of work has been conducted with male-to-female transgender populations. This research synthesis comprehensively reviews HIV and STI research in female-to-male (FTM) transgender adults. A paucity of research exists about HIV and STIs in FTMs. Only 25 peer-reviewed papers (18 quantitative, 7 qualitative) and 11 'grey literature' reports were identified, most in the US or Canada, that include data identifying HIV and STI risks in FTMs (five with fully laboratory-confirmed HIV and/or STIs, and five with partial laboratory confirmation). Little is known about the sexual and drug use risk behaviours contributing to HIV and STIs in FTMs. Future directions are suggested, including the need for routine surveillance and monitoring of HIV and STIs globally by transgender identity, more standardised sexual risk assessment measures, targeted data collection in lower- and middle-income countries, and explicit consideration of the rationale for inclusion/exclusion of FTMs in category-based prevention approaches with MSM and transgender people. Implications for research, policy, programming, and interventions are discussed, including the need to address diverse sexual identities, attractions, and behaviours and engage local FTM communities.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              HIV Testing Among Transgender Women and Men — 27 States and Guam, 2014–2015

              Transgender persons are at high risk for human immunodeficiency virus (HIV) infection; in a recent analysis of the results of over nine million CDC funded HIV tests, transgender women* had the highest percentage of confirmed positive results (2.7%) of any gender category ( 1 ). Transgender men, † particularly those who have sex with cisgender § men, are also at high risk for infection ( 2 ). HIV testing is critical for detecting and treating persons who are infected and delivering preventive services to those who are uninfected. CDC recommends that persons at high risk for HIV infection be screened for HIV at least annually, although transgender persons are not specified in the current recommendations. CDC analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS) to describe HIV testing among transgender women and men and two cisgender comparison groups in 27 states and Guam. After adjusting for demographic characteristics, transgender women and men had a lower prevalence of ever testing and past year testing for HIV (35.6% and 31.6% ever, and 10.0% and 10.2% past year, respectively) compared with cisgender gay and bisexual men (61.8% ever and 21.6% past year) and instead reported testing at levels comparable to cisgender heterosexual men and women (35.2% ever, and 8.6% past year). This finding suggests that transgender women and men might not be sufficiently reached by current HIV testing measures. Tailoring HIV testing activities to overcome the unique barriers faced by transgender women and men might increase rates of testing among these populations. BRFSS is an annual, state-based, random-digit–dialed cellular and landline telephone survey of the noninstitutionalized U.S. adult population. ¶ Gender identity was uniformly assessed in an optional module used by 20 jurisdictions** in 2014 and 22 jurisdictions †† in 2015. Fourteen jurisdictions participated in the module during both years, six participated only in 2014, and eight participated only in 2015, for a total of 28. Jurisdiction-specific response rates ranged from 33.0% to 59.2% §§ and 34.4% to 57.6% ¶¶ in 2014 and 2015, respectively. Transgender respondents were defined as those who answered affirmative to the question if they considered themselves to be transgender. Those who answered affirmative were asked to identify as male-to-female (defined as transgender women in this report), female-to-male (defined as transgender men in this report), or gender nonconforming. Because of small sample size, responses from gender nonconforming persons (n = 272) were not included in this analysis. Pooled data collected in 2014 and 2015 were used to compare demographic characteristics and HIV testing among transgender and cisgender respondents. Cisgender men who reported sexual orientations of gay or bisexual represent a group at high risk for HIV infection ( 3 ). Cisgender men and women who reported an orientation of straight (hereafter referred to as cisgender heterosexual men and women) represent a group at lower risk for infection ( 4 ). The proportion of respondents who reported ever and past year HIV testing was calculated, and unadjusted prevalence ratios and 95% confidence intervals were estimated to identify characteristics associated with ever testing among transgender women and men. Multivariable logistic regression models compared self-reported prevalence of ever and past year testing among transgender women and men with cisgender gay and bisexual men while adjusting for characteristics associated with testing in univariate models (p<0.10). All estimates were weighted to account for the complex multistage sampling design; because only 14 of 28 jurisdictions participated in the optional module during both years of data collection, weights for these 14 jurisdictions were averaged across the 2-year period to account for varying levels of participation over time. Estimates with relative standard error ≥30% were not reported. During 2014–2015, 28 jurisdictions collected data on gender identity, resulting in a total sample of 732 transgender women, 451 transgender men, 3,798 cisgender gay and bisexual men, and 301,524 cisgender heterosexual men and women (Table 1). The unadjusted prevalence of ever testing for HIV was 37.5% among transgender women, 36.6% among transgender men, 66.2% among cisgender gay and bisexual men, and 35.2% among cisgender heterosexual men and women. The unadjusted prevalence of past year testing was 11.7% among transgender women, 12.4% among transgender men, 27.5% among cisgender gay and bisexual men, and 8.6% among cisgender heterosexual men and women. TABLE 1 Selected demographic characteristics and HIV testing behaviors among transgender and cisgender respondents* — Behavioral Risk Factor Surveillance System, 27 states and Guam, † 2014–2015 Characteristic Transgender women Transgender men Cisgender gay and bisexual men§ Cisgender heterosexual men and women¶ No. %** (95% CI) No. %** (95% CI) No. %** (95% CI) No. %** (95% CI) Total 732 100 — 451 100 (—) 3,798 100 (—) 301,524 100 (—) Race/Ethnicity White, non-Hispanic 527 60.6 (52.8–67.9) 309 49.2 (37.9–60.6) 2,929 67.1 (63.7–70.3) 242,370 71.1 (70.7–71.5) Black, non-Hispanic 67 13.3 (9.3–18.7) 43 11.4 (6.6–18.9) 233 11.8 (9.7–14.5) 21,166 12.0 (11.7–12.3) Hispanic or Latino 46 13.2 (8.1–21.0) 48 29.0 (18.6–42.2) 250 12.8 (10.2–15.8) 14,320 11.0 (10.7–11.4) Other, non-Hispanic 77 12.9 (7.9–20.2) 42 —†† 338 8.3 (6.9–10.1) 19,890 5.9 (5.7–6.1) Age group (yrs) 18–24 55 14.2 (9.9–19.8) 30 15.6 (8.7–26.4) 434 21.9 (19.0–25.1) 14,166 11.7 (11.4–12.0) 25–44 146 29.1 (22.3–37.0) 98 45.2 (33.7–57.2) 893 33.4 (30.5–36.5) 60,098 31.5 (31.1–31.9) 45–64 322 40.3 (33.6–47.4) 185 25.0 (18.3–33.1) 1,582 33.9 (31.2–36.7) 122,321 36.2 (35.9–36.6) ≥65 209 16.4 (12.6–21.1) 138 14.2 (10.0–19.8) 889 10.8 (9.5–12.3) 104,939 20.6 (20.4–20.8) Education
                Bookmark

                Author and article information

                Contributors
                (View ORCID Profile)
                Journal
                Sexually Transmitted Infections
                Sex Transm Infect
                BMJ
                1368-4973
                1472-3263
                August 19 2020
                September 2020
                September 2020
                June 30 2020
                : 96
                : 6
                : 422-427
                Article
                10.1136/sextrans-2020-054474
                32605930
                120ab645-32e4-42c9-97fd-b0c1e3c9eb6e
                © 2020
                History

                Comments

                Comment on this article